The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation.

Allogeneic stem cell transplantation is used in the treatment of younger patients with severe hematological diseases, especially hematological malignancies, and acute graft versus host disease (GVHD) is then an important immune-mediated posttransplant complication. Several risk factors for acute GVHD have been identified, including pretransplant factors that possibly influence the posttranspant course through their effects on host immunocompetent cells. Metabolic regulation is important for immunoregulation, and we therefore investigated whether the pretransplant metabolic status of allotransplant recipients was associated with later acute GVHD. In our population-based study we investigated the systemic (serum) metabolic profile for 86 consecutive allotransplant recipients. The samples were collected before start of the pretransplant conditioning therapy. Patients who developed later acute GVHD especially showed altered pretransplant amino acid metabolism, including (1) altered metabolism of immunoregulatory branched chain amino acids (leucine, isoleucine and valine); and (2) altered levels of potentially proinflammatory tyrosine metabolites (p-cresol sulphate, 3-phenylpropionate) formed by the gastrointestinal microbial flora. However, isobutyrylcarnitine and propyonylcarnitine levels were also altered; the carnitines are important for the transport of fatty acids and may also be important for the release of immunoregulatory cytokines in allotransplant recipients. These metabolic alterations were associated with an ongoing pretransplant acute phase reaction or early hematopoietic/immune reconstitution. Thus, allotransplant recipients developing acute GVHD showed altered preconditioning/pretransplant levels of several immunoregulatory metabolites. Our hypothesis is that these metabolites alter or activate recipient immunocompetent cells and thereby enhance or initiate anti-recipient immune reactivity.

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents an effective therapeutic strategy in younger patients with a variety of severe hematological disorders. The strong antileukemic effect of allo-SCT is due to the intensive conditioning therapy, nonspecific graft versus host reactivity and specific graft versus leukemia (GVL) effects (Kersey 2010). However, these beneficial effects are counteracted by the risk of severe and potentially lethal posttransplant complications including serious infections, immune-mediated acute and chronic graft-versus-host disease (GVHD) and treatment-related organ toxicity (Gooley et al. 2010). The decision to recommend allo-SCT therefore thus has to be individualized and based on the expected long-term disease-free survival with conventional chemotherapy alone versus the risk of relapse and the risk of treatment-related mortality/morbidity after allogeneic transplantation. Several strategies based on pretransplant prognostic factors of long-term survival have been suggested (Gratwohl 2012; Servais et al. 2014; Sorror 2009). However, these systems are mainly based on clinical factors and may be improved if additional biological factors could be incorporated, e.g. the pretransplant serum profiles of immunoregulatory cytokines that differ between allotransplant recipients with and without posttransplant acute GVHD (Reikvam et al. 2012a, b, 2013).

Metabolomic profiling, or metabolomics, is the study of low molecular weight compounds in biological fluids and metabolites can then be defined as non-peptide molecules often representing end products of cellular activity. Therefore, changes in metabolite concentrations reveal the range of biochemical effects induced by diseases and/or therapeutic intervention. During the last years metabolomic profiling has become possible through the development of new technologies, and studies in patients with acute myeloid leukemia (AML) have described both a specific metabolic profile associated with mutations in the isocitrate dehydrogenases 1 and 2 genes (IDH 1/2) (Wang et al. 2013) as well as a distinct glucose metabolism signature associated with resistance to cytarabine and decreased survival (Chen et al. 2014).

The overall nutritional/metabolic status as well as the levels of several single metabolites is important for immunoregulation (Tvedt et al. 2016). In this context we have investigated whether pretransplant metabolic profiles reflects a risk of posttranspant acute GVHD, and we describe associations between the pretransplant metabolic profile and the posttransplant clinical course.

Materials and methods

Patients

The study was approved by the local Ethics Committee (Regional Ethics Committee III, University of Bergen, Norway) and samples collected after written informed consent. The study included 86 consecutively allotransplanted adult patients (54 men and 32 women; median age 45 years with range 15–69 years) from a defined geographic area (Norwegian Health Regions III, IV and V) transplanted with a family donor. The decision to perform an allotransplantation was taken by the Norwegian Advisory Board for Stem Cell Transplantation and based on national guidelines. Thus, our study is population-based and includes an unselected and consecutive group of well-characterized patients.

The clinical characteristics of the patient are given in Table 1 and Supplementary Fig. 1. Most patients received GVHD prophylaxis with cyclosporine A and methotrexate, only two patients received cyclosporine A alone. Patients were transplanted with granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells derived from HLA-matched family donors (aplastic anemia patients received bone marrow grafts). Neutrophil reconstitution was defined as three consecutive days with neutrophil counts of at least 0.2 × 109/L, and platelet reconstitution as stable platelet counts exceeding 20 × 109/L for at least three consecutive days. All patients were carefully examined for and classified with regard to comorbidity according to Sorror et al. (2009); none of the patients had liver or renal disease and the overall comorbidity score was low (1 or 0). Sinusoidal obstruction syndrome was not diagnosed in any patient.

Table 1

Demographical, clinical and laboratory data for the 86 patients included in the study

Patient characteristics	Observation
Demographic data and disease history
Gender (numbers)
Male/female	54/32
Age (years, median and range)	45 (15–69)
Height (cm, median and range)	176 (149–197)
Weight (kg, median and range)	71 (42–133)
BMI (kg/m2, median and range)	23.3 (16.6–39.7)
Diagnosis (numbers)
AML	38
MDS	16
ALL	19
CML	5
CMML	2
CLL	1
PMF	2
AA	3
Disease status (numbers)
CR1	51
CR2	15
No remission	20
Conditioning regimen (numbers)
Bu + Cy	69
ATG + Cy	4
TBI + Cy	2
TBI + Eto	1
Flu + Bu	9
Flu + Cy	1
Acute GVHD (numbers)	31 out of 77 evaluable patients
Reconstitution (day posttransplant)
Neutrophils (day; median and range)
>0.2 × 109/L (3 consecutive days)	16 (6–52)
Platelets (day; median and range)
>20 × 109/L (3 consecutive days)	15 (9–33)
Baseline pretransplant status
WBC (median and range)	3.7 (0.5–14.1) × 109/L
Hb (median and range)	10.4 (7.8–14.1) g/dL
Platelets (median and range)	141 (7–721) × 109/L
CRP (median and range)	5 (1–120) mg/L
LDH (median and range)	187 (92–1655) UI/dL

Values are unless otherwise stated given as median and range in parenthesis. Height and weight were registered at the start of conditioning therapy

BMI body mass index, AML acute myelogenous leukemia, MDS myelodysplastic syndrome, ALL acute lymphoblastic leukemia, CML chronic myelogneous leukemia, CMML chronic myelomonocytic leukemia, CLL chronic lymfocytic leukemia, PMF primary myelofibrosis, AA aplastic anemia, CR complete remission, Bu busulphan, Cy cyclophosphamide, ATG anti-thymoglobulin, TBI total body irradiation, Eto etoposide, Flu fludarabine, GVHD graft versus host disease, WBC white blood cell count, Hb hemoglobin, CRP C-reactive protein, LDH lactate dehydrogenase

All samples were collected before start of conditioning therapy (median 19 days before, range 3–56 days). GVHD was diagnosed according to generally accepted criteria (Filipovich 2008). Briefly, the diagnosis of acute GVHD was generally based on careful clinical evaluation and additional skin biopsies for patients with skin involvement alone. The diagnosis of acute GVHD for the patients with liver and/or gastrointestinal involvement was also based on careful clinical evaluation and additional biopsies (including eight with skin biopsies and five with biopsies from the gastrointestinal tract) except for one patient with liver involvement for whom acute GVHD was a clinical diagnosis.

Sample preparation, analysis of metabolite serum levels and bioinformatical analyses

All venous blood samples were collected into sterile plastic tubes (BD Vacutainer® SST™ Serum Separation Tubes, Becton-Dickenson; Franklin Lakes, NJ, USA) and allowed to coagulate for 120 min at room temperature (18 °C) before centrifugation (300 g for 10 min) and serum collection. All samples were immediately frozen at −70 °C until analyzed.

Metabolomic profiling analysis of all samples was carried out in collaboration with Metabolon® as described previously (Evans et al. 2014). Each sample was accessioned into the Metabolon LIMS system and was assigned by the LIMS a unique identifier, and was used to track all sample handling, tasks, results, etc. The samples (and all derived aliquots) were tracked by the LIMS system. Samples were prepared using the automated MicroLab STAR® system from Hamilton Company. A recovery standard was added prior to the first step in the extraction process for QC purposes. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min, followed by centrifugation. The resulting extract was divided into four fractions: one for analysis by UPLC-MS/MS with positive ion mode electrospray ionization, one for analysis by UPLC-MS/MS with negative ion mode electrospray ionization, one for analysis by GC–MS, and one sample was reserved for backup. Samples were placed briefly on a TurboVap® (Zymark) to remove the organic solvent. For LC, the samples were stored overnight under nitrogen before preparation for analysis. For GC, each sample was dried under vacuum overnight before preparation for analysis.

Bioinformatical analyses were performed using the J-Express (MolMine AS, Bergen, Norway) (Stavrum et al. 2008). For hierarchical clustering all values were median variance standardized and log(2) transformed. The complete linkage was used as linkage method, and for distance measured the Pearson correlation was used. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, IL, USA). The Chi Square test was used to compare different groups. Unless otherwise stated p values <0.05 were regarded as statistically significant.

Results and discussion

Allotransplant recipients are heterogeneous with regard to the pretransplant serum metabolite profile

Our study included 86 consecutive patients. Nine of these patients (6 men and 3 women, median age 44 years with range 25–56 years) died from early non-GVHD complications (i.e. septicemia, organ toxicity) that developed within 14 days posttransplantation and later progressed to irreversible multiorgan failure. Seven of these patients had AML (one secondary to myelodysplastic syndrome); they were all in first complete remission prior to transplantation except for one patient who was in second complete remission. The two last patients had T-ALL and aplastic anemia, respectively. All patients received myeloablative conditioning treatment, 7 of them with busulfan plus cyclophosphamide. Only three of these patients showed signs of hematopoietic reconstitution at the time of death, and 8 of them died before day +25 posttransplant (median survival 21 days after transplantation, range 7–43 days). Death due to severe septicemia was seen only for one patient (pseudomonas aeruginosa, death on day +7). Thus, these patients did not differ from the other patients with regard to these clinical characteristics. The nine patients were not included in our comparison of patients with and without acute GVHD because (1) multiorgan failure developed before acute GVHD would usually be expected, and (2) the complexity of the clinical situation made it impossible to diagnose acute GVHD according to generally accepted criteria but it should be emphasized that none of the patients showed any of the typical symptoms/signs consistent with acute GVHD in the skin, liver or gastrointestinal tract.

A total of 766 metabolites were analyzed in the pretransplant serum samples for all 86 patients (Supplementary Table 1). These metabolites could be divided into the eight main categories (corresponding number of metabolites) amino acids (156), peptides (92), carbohydrates (24), energy metabolism (9), lipids (298), nucleotides (36), cofactors/vitamins (27) and xenobiotics (124). These metabolites represent a broad evaluation of the major metabolic pathways in the cell (Supplementary Table 1).

We first compared the pretransplant metabolic profile of the 31 patients with and the 46 patients without acute GVHD; both principal component analysis and hierarchical clustering then failed to distinguish between these two patient subsets (data not shown). These observations probably reflect the metabolic heterogeneity of our patients when comparing the overall serum metabolite profiles.

Patients developing acute GVHD have altered pretransplant levels of several immunoregulatory metabolites

We then performed a random forest analysis of our patients; this is a supervised classification statistical method that can be used for biomarker identification. By using this methodological approach we could identify metabolic biomarkers that distinguished between patients with and without acute GVHD with a predictive accuracy of 71.5 % (Fig. 1). This number is thus greater than the random chance alone (~50 %), suggesting that the identified metabolites are candidate biomarkers for predicting risk of GVHD. The figure shows the top 30 metabolites based on the importance for the separation of the two groups. A majority of these metabolites (14 out of 30) are involved in amino acid metabolism, especially the metabolism of immunoregulatory branched chain amino acids (BCAA), but other immunomodulatory metabolites were also identified:

Fig. 1

Random forest analysis of pretransplant metabolite levels; identification of metabolites showing increased serum levels in patients with posttransplant acute GVHD. Random forest analysis could distinguish between the metabolic signatures of patients with and without acute GVHD with a predictive accuracy of 71.5 %; this number is higher than random chance alone (~50 %) and suggests that these metabolites are candidate biomarkers for increased risk of acute GVHD. The figure presents the top 30 metabolites based on importance to separate the two patient groups

p-cresol sulphate (de Loor et al. 2005) and 3-phenylpropionate (Nordlund et al. 2012) are tyrosine derivatives that can be formed by the intestinal bacterial flora and later be absorbed. p-cresol sulphate seems to have both proinflammatory and proapoptotic effects (de Loor et al. 2005).

Isobutyrylcarnitine and propyonylcarnitine levels were also altered; the carnitines are important for the transport of fatty acids and may also be important for the release of immunoregulatory cytokines in allotransplant recipients (Zatarain and Savani 2012).

Propionylcarnitine have effects on endothelial cells and may thereby influence the trafficking of immunocompetent cells (Andreozzi 2009; Malaguarnera 2012).

Hydantoin-5-propionic acid, the altered level of this metabolite is consistent with altered metabolism of valine and/or isoleucine. Furthermore, 3-methylcrotonylglycine is formed by the metabolism of BCAAs and seems to disrupt mitochondrial energy homeostasis through effects on the respiratory chain, but there is also altered formation of free radicals (Moura et al. 2012).

Thus, altered pretransplant metabolism of immunoregulatory amino acids and/or altered pretransplant levels of immunoregulatory metabolites seem to reflect an increased risk GVHD.

Acute GVHD patients show altered pretransplant metabolism of immunoregulatory branched chain amino acids

We also performed an additional pathway enrichment analysis based on the number of altered metabolites relative to the total number of all analyzed metabolites in a metabolic pathway; this was compared with the total number of altered metabolites relative to all the metabolites analyzed. We identified several metabolic pathways that were enriched in the 31 patients with acute GVHD compared with the 46 patients without this posttransplant complication (Fig. 2, Supplementary Table 1), and this alternative analysis showed several similarities to the previous random forest analysis. Firstly, the metabolism of branched chain amino acids (i.e. leucine, isoleucine and valine) differed between patients with and without later acute GVHD. Secondly, tyrosine metabolism was also found to be altered; this observation together with the observed differences in tryptophan, lysine, phenylalanine, and secondary bile acid metabolism suggest that the pretransplant gut function/microbiome is altered in patients who develop acute GVHD (all 86 patients included in the analysis). Thirdly, tryptophan metabolism can also be important in immunoregulation, but even though this term was also increased tryptophan metabolism seems to be less important for the risk of acute GVHD than BCAA metabolism.

Fig. 2

Pathway enrichment analysis of metabolic profiles associated with acute GVHD. The pathway enrichment analysis was used to identify pathways that were altered in pretransplant samples for patients with later acute GVHD compared to patients without acute GVHD. A pathway enrichment value greater than 1 indicates that the pathway was increased in acute GVHD patients. The top ranked metabolic pathways (p < 0.05, enrichment value >2) identified by this comparison (GVHD(+) versus GVHD(−) patients) are given in the figure

We further analyzed the metabolites belonging to the top five ranked enriched metabolic pathways: (1) fatty acid/BCAA metabolism; (2) leucine, isoleucine and valine metabolism; (3) fatty acid synthesis; (4) guannidino and acetamido metabolism; and (5) inositol metabolites. We next performed a hierarchical clustering analysis (Pearson’s Correlation, complete linkage) based on the 44 metabolites that belonged to these five terms (Fig. 3). There was very little overlap between the five enriched metabolic pathways, and a major part of these metabolites were included in the term leucine, isoleucine and valine metabolism (31 of the 44 metabolites). Based on the cluster analysis we were able to identify two main patient clusters; for one cluster 19 out of 34 patients developed acute GVHD whereas for the other cluster only 11 out 52 developed GVHD. This difference was statistically significant (Chi Square test, χ2 = 12.69, p = 0.0004).

Fig. 3

Hierarchical clustering analysis identified two patient subset highly associated to GVHD. We performed a hierarchical clustering analysis (Pearsons Correaltion, complete linkage) based on the 44 metabolites included in the top five ranked terms from the pathway enrichment analysis presented in Fig. 2. Based on the 44 metabolites belonging to these five terms, we performed a hierarchical clustering analysis. The heat map and according dendrograms are shown in the figure. Red indicates high value and green low value, and the five metabolic pathways can be seen in the left part of the figure. We identified two main clusters; the left main cluster includes a major part of patients who later developed acute GVHD, whereas the right cluster included mainly patients without posttransplant acute GVHD. The frequency of acute GVHD patients differed significantly between the clusters (Chi Square test, χ2 = 12.69, p = 0.0004)

We also included the nine patients with early irreversible multiorgan failure in the final clustering analysis; these patients seem to be a heterogeneous subset and the distribution of these patients did not differ between the two main subsets. These nine patients also showed a wide variation in the serum levels of individual metabolites associated with acute GVHD (Fig. 1) and with no differences from the other patients. Taken together these observations suggest that these patients with early death do not represent a group of patients dying from hyperacute GVHD. Other causes of multiorgan failure (i.e. infections, treatment toxicity) seem to be more likely.

The metabolic profile associated with an ongoing pretransplant acute phase reaction differs from the acute GVHD profile

We then investigated how the pretransplant metabolic profile differed between patients with and without signs of ongoing inflammation; we then used the serum level of C-reactive protein (CRP) as a marker for an acute phase reaction and compared patients with CRP < 10 mg/L (no inflammation, 58 patients) and CRP > 10 mg/L (with inflammation, 28 patients). An initial pathway enrichment analysis identified several metabolic pathways that differed between these two patient subsets (Fig. 4, Supplementary Table 1); 15 terms with a pathway enrichment value exceeding 2 were identified but these terms differed from the acute GVHD analysis (see above) and did not include the branched chain amino acid terms. Furthermore, when doing a random forest analysis the 30 highest ranked metabolites included only 6 amino acid metabolites, 8 lipid metabolites were included together with 4 carbohydrates, 5 nucleotides and 7 peptide metabolites. Thus, these methodological approaches identified other term/metabolites that differed from the acute GVHD-associated profile, suggesting that the association between metabolic profile and acute GVHD is not caused by a pretransplant inflammation/acute phase reaction.

Fig. 4

Pathway enrichment analysis of metabolic profiles associated with an ongoing pretransplant acute phase reaction. The pathway enrichment analysis was used to identify metabolites/pathways that were altered in pretransplant samples derived from patients with an ongoing pretransplant acute phase reaction (i.e. serum CRP > 10 mg/L) compared to patients with normal CRP level. A pathway enrichment value greater than 1 indicates that the pathway was increased in patients with an acute phase reaction. The top ranked metabolic pathways (p < 0.05, enrichment value >2) identified by this comparison are given in the figure

We finally performed a hierarchical clustering analysis based on the results from the analyses (Pearson’s Correlation, complete linkage, Fig. 5). Based on the cluster analysis we identified two main patient clusters: one main cluster that included most patients with increased CRP levels and another including most patients with normal/low CRP levels; this difference was highly significant (Chi Square test, χ2 = 8.02, p = 0.0046).

Fig. 5

Hierarchical clustering analysis identified two patient subset highly associated with pretransplant inflammation. The hierarchical clustering analysis (Pearsons Correaltion, complete linkage) was based on the 64 metabolites that belonged to the 11 terms/those metabolic pathways showing enrichment score >3.0 and p < 0.001. The heat map together with dendrograms is presented in the figure. Red indicates high value and green low value, and the metabolic pathways are shown to the left. We identified two main clusters; one including several patients with an acute phase reaction (left) and another including few of these patients (right). These two main clusters differed significantly with regard to the frequency of pretransplantation inflammation processes (Chi Square test, χ2 = 8.02, p = 0.0046)

Patients with late hematological reconstitution have a metabolomic profile characterized by altered purine and pyrimidine metabolism

None of the patients showed primary graft failure, and we defined early reconstitution as three consecutive days with neutrophil counts >0.2 × 109/L within day +16 posttransplant. We also did a pathway enrichment analysis, and several metabolic pathways were altered when comparing patients with early reconstitution and late reconstitution (Supplementary Fig. 2). However, pathways associated with early reconstitution showed only minor overlap with GVHD-associated pathways.

Pretransplant metabolic immunoregulation: a risk factor for acute GVHD?

The risk of acute GVHD differs between patients and several pretransplant factors are among the risk factors. Our present results show that pretransplant levels of immunoregulatory metabolites reflect a risk of posttransplant acute GVHD.

Our study included a consecutive group of patients with a family donor from a defined geographic area during a defined time period. The large majority of patients received myeloablative conditioning treatment and the same GVHD prophylaxis, and the guidelines for allotransplantation did not change during the study period. Thus, the patients represent a well-defined and relatively homogeneous group of allotransplant recipients.

As explained above we excluded nine patients who died early without the classical diagnostic signs of acute GVHD, but for all except one patient with septicemia the cause of the multiorgan failure could not be identified. One possible cause is treatment toxicity, another possibility being hyperacute GVHD. However, our metabolic studies could not detect any similarities between these nine patients and the acute GVHD patients; this makes the last explanation less likely.

Pretransplant characteristics are important for the risk of posttransplant acute GVHD, e.g. advanced disease, the conditioning regimens and previous viral infections (Chaidos et al. 2007; Gratwohl 2012). However, several studies have investigated the associations between serum or plasma biomarker levels and the risk of posttransplant complications, including acute GVHD. Firstly, the risk of serious complications early after allotransplantation is associated with the preconditioning serum profile of immunoregulatory and angioregulatory mediators, and the same seems to be true for systemic levels of endothelial cell-derived adhesion molecules (Lindås et al. 2014; Reikvam et al. 2012a). Secondly, an association between serum levels of angioregulatory Angiopoietin-2/Tie2 and relapse-free survival was described for a selected group of high-risk patients with only 17 out of 90 patients being in complete remission prior to transplantation (Koenecke et al. 2010; Kümpers et al. 2008). These patients are thus not comparable to our unselected patients. Thirdly, in a pediatric study Porkholm et al. (Porkholm et al. 2013), described that pretransplant (but postconditioning) high Angiopoietin-2 plasma levels were associated with increased risk of gastrointestinal GVHD and non-relapse mortality. Thus, our present study is the first to suggest an association between the preconditioning metabolic profile and risk of later acute GVHD.

Tyrosine is synthesized from the essential amino acid phenylalanine and can be fermented in the gut, one important product being p-Cresol (de Loor et al. 2005). Phenols can also be formed by gut fermentation, including phenyl-propionic acid (Nordlund et al. 2012). A majority of our patients had acute leukemia in complete remission and had been treated with intensive antileukemic chemotherapy prior to the transplantation; this treatment causes mucositis and may cause severe gastrointestinal complications (Shafi and Bresalier 2010), and the production of p-cresols and phenols depends on the intestinal microenvironment, including intestinal flora and pH (Nakabayashi et al. 2011). The altered levels of such metabolites may thus reflect disturbances in the gastrointestinal function or the intestinal flora that are associated with a risk of acute GVHD. These metabolites can originate from bacterial fermentation in the large intestine (de Loor et al. 2005; Nordlund et al. 2012); their altered pretransplant levels may then predispose to acute GVHD through effects on donor immunocompetent cells.

p-Cresol is absorbed from the gut and detoxified in the liver by conjugation (sulfatation and glucuronidation), the main product in serum being p-cresylsulfate and p-cresylglucuronide (de Loor et al. 2005). However, free p-cresol can also be detected in the circulation (Bammens et al. 2006; de Loor et al. 2005; Meijers et al. 2010). p-cresyl sulfate (and also p-cresyl glucuronide) is regarded as a proinflammatory mediator (Poveda et al. 2014); it activates leukocyte free radical production, has proapoptotic effects (Poveda et al. 2014) and alters the endothelial response to inflammatory cytokines as well as the cytokine release by monocytes (Schepers et al. 2007). Thus, these metabolites can possibly alter inflammatory processes both by direct effects on immunocompetent cells and by altered cell trafficking/migration due to altered endothelial cell functions.

Carnitine is an essential dietary nutrient and it acts as a carrier of fatty acids across the inner membrane of the mitochondrial membrane (Malaguarnera 2012). Oral propyonyl-L-carnitine has been tried in the treatment of human diseases (Andreozzi 2009; Malaguarnera 2012), mainly cardiovascular disease, but it has also shown beneficial effects in a randomized, double-blind, placebo-controlled study of patients with ulcerative colitis, i.e. an autoimmune disease (Mikhailova et al. 2011). The vascular effects of propyonyl-L-isocarnitine include reduced plasma extravasation, modulation of endothelin-prostaglandin effects, vasodilatation, and increased fatty acid oxidation in vascular tissue. These effects may then affect the trafficking of immunocompetent cells and thereby also the risk of acute GVHD.

Both in vitro and in vivo studies suggest that the branched chain amino acids have immunoregulatory effects that at least partly are mediated through mTOR activation (Kim et al. 2012). Firstly, leucine has been shown to increase the release of leptin in animal models (Lynch et al. 2006), another important metabolic immunoregulator (Agrawal et al. 2011). Secondly, especially valine seems important for the differentiation of normal monocytes to specialized and mature antigen-presenting dendritic cells, and this differentiation is then associated with a PI3K-Akt-mTOR induced metabolic switch to glycolysis (Kakazu et al. 2007). Finally, both leucine, isoleucine or valine seem to enhance the proliferation of activated T cells (Calder 2006), and animal studies suggest that oral intake of isoleucine has an immunoregulatory function in the gut (Zhao et al. 2014). Finally, several studies suggest that BCAA have immunostimulatory effects not only in animal models but also in humans (Alam et al. 2011; Bassit et al. 2002; Cerra et al. 1984; Freund et al. 1978; Nuwer et al. 1983). Thus, our study suggests that the pretransplant status of the immunoregulatory system is important for the risk of posttransplant acute GVHD.

We also analysed the metabolites associated with a pretransplant acute phase reaction (i.e. increased serum CRP levels), but the metabolic terms as well as individual metabolites associated with increased CRP levels differed from the terms/metabolites associated with acute GVHD. The same was true for terms/metabolites associated with early hematopoietic reconstitution. These observations suggest that the metabolic mechanisms associated with the risk of acute GVHD are independent of the acute phase reaction and bone marrow recovery.

Concluding remarks

Our present study suggests that the pretransplant metabolic profile reflects the risk of developing acute GVHD after allotransplantation. Several of the metabolites or the metabolic pathways that were observed to reflect this risk (tyrosine metabolites, BCAAs, fatty acid metabolism), are important for immunoregulation and may thus be directly involved in the development of acute GVHD through effects on donor immunocompetent cells. The question whether pretransplant metabolic interventions (i.e. nutritional support) will decrease the risk of posttransplant acute GVHD has to be addressed in future clinical studies.

Below is the link to the electronic supplementary material.

An overview of the 86 allotransplants recipients included in the study. The figure presents the clinical characteristics of the 86 patients. The vertical columns show the presence of acute GVHD (left), ongoing acute phase reaction (inflammation) at the start of condition therapy (middle) and time until reconstitution (right). The red color indicates development of acute GVHD, serum CRP level >10 mg/L and time to neutrophil reconstitution later than day +16 (neutrophil count >0.2 x 109/L), respectively. (EPS 823 kb)

Pathway enrichment analysis of metabolites associated with late neutrophil reconstitution. The pathway enrichment analysis was used to identify metabolites/pathways that were altered in pretransplant samples derived from patients with early neutrophil reconstitution compared with patients with later reconstitution; early neutrophil reconstitution then being defined as neutrophil counts >0.2 x 109/l within day +16 after the transplantation. A pathway enrichment value greater than 1 indicates that the pathway was associated with early reconstitution. The top ranked metabolic pathways (p<0.05, enrichment value >2) identified by this analysis/comparison are given in the figure. (TIFF 198 kb)

Supplementary material 3 (PDF 729 kb)